Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...

Generics are drugs that are designed to replicate the original branded drug ... development, and clinical trials. These new discoveries undergo years of human and animal testing before being ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days in the fridge. Compounded semaglutide, which contains the same active ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

The research-ready Virtual Registry was built as part of the Helix Research Network (HRN). The cohort consists of whole Exome+® sequencing profiles for 15,000 GLP-1 agonist treat ...